MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
Tissue-based test volume declined 11% year over year, while unexpected sales-force turnover disrupted execution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MDxHealth (MDXH) suspended its full-year 2026 revenue guidance and announced preliminary third-quarter revenue from continuing operations of approximately $22.7 million. The withdrawn guidance was $110–115 million. Expected revenue for the quarter ended September 30, 2026, matches $22.7 million a year earlier, re-presented to exclude discontinued Resolve mdx.
Tissue-based test volume fell 11% year over year to 11,232. Liquid-based Exo mdx volume was 11,792 versus 4,600 a year earlier; the prior-year figure included Select mdx and Exo mdx from its September 2025 acquisition. Cash and cash equivalents were approximately $31.7 million at September 30. The company attributed revenue below expectations to unexpected sales-force turnover following Resolve mdx's discontinuation and plans to reinforce affected territories. Full results and an earnings call are scheduled for November 12.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointExo mdx volume of 11,792 compares with 4,600 prior-year liquid-based tests, including Select mdx and Exo mdx.
- Minor point. Forward-looking: it has not happened yet and may not happen.Territory reinforcement is planned to address areas affected by sales-force turnover.
- Minor point. Forward-looking: it has not happened yet and may not happen.Return to growth within its end markets remains the company's expectation.
Negative
- Major pointFull-year 2026 revenue guidance of $110–115 million suspended.
- Moderate pointPreliminary continuing-operations revenue of approximately $22.7 million expected, flat year over year and below company expectations.
- Moderate pointTissue-based test volume declined 11% year over year to 11,232.
- Moderate pointUnexpected sales-force turnover disrupted execution following Resolve mdx's discontinuation.
- Minor pointPreliminary financial estimates are unaudited and subject to change after quarter-end close and review procedures.
News Explained
The reported
Details
Market move: MDXH -8.96% vs previous close. 2026 revenue guidance update
On Oct 15, the day this news came out, the latest delayed price for MDXH is 8.96% below the previous close. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner has recorded 21 alerts for this stock so far that day. The latest delayed price is $0.55. Relative volume is elevated at 2.8x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Q3 revenue
- Approximately $22.7 million
- Preliminary Q3 2026; compared with $22.7 million in Q3 2025
- Full-year revenue guidance
- $110–115 million
- Full-year 2026 guidance; suspended
- Tissue-based test volume
- 11,232 tests; decrease of 11%
- Q3 2026 compared with the prior-year period
- Liquid-based test volume
- 11,792 tests vs. 4,600
- Q3 2026 vs. prior year, which included Select mdx and Exo mdx
- Cash and cash equivalents
- Approximately $31.7 million
- As of September 30, 2026
Historical Context
-
Reported Q2 revenue growth from continuing operations, with ExoDx-driven liquid-based expansion and higher operating loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
continuing operations financial
discontinued operation financial
unaudited financial
epigenomic medical
exosomal medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, CA – October 15, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of
The Company expects to report third quarter 2026 revenue from continuing operations of approximately
Michael K. McGarrity, CEO of mdxhealth, commented: “Third quarter revenue fell short of our expectations. Following the discontinuation of Resolve mdx, we experienced unexpected turnover within our sales force catalyzed by aggressive targeting from recruiters. While we have a disciplined process which has served as the foundation of our forecast accuracy over the past three years, that process was clearly disrupted by this recent impact on our sales force.
“Although this led to an interruption in the progress we reported in Q2, we are focused on fortifying impacted territories and returning to consistent execution. Importantly, we do not believe these factors represent a change in the reputation that we have built with our customer base, the underlying clinical demand for our products, or our long-term market opportunity, and we expect to return to growth within these end markets. We will provide additional detail on our corrective actions and progress when we report our full third quarter results and host our earnings call on November 12.”
The preliminary financial information in this press release is unaudited, is based on management’s initial review of the Company’s results for the quarter ended September 30, 2026, and is subject to change upon completion of the Company’s quarter-end financial close and review procedures. The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to this preliminary financial information. Actual results may differ materially from these preliminary estimates.
About mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
John Fraunces
Managing Director
Tel: +1 917 355 2395
Forward-Looking Statement: This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding the Company’s preliminary unaudited financial results for the third quarter of 2026; expected future operating results; our strategies, positioning, resources, capabilities, market opportunities and expectations for future events or performance; and the anticipated timing and benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; our ability to recruit, train and retain qualified sales personnel and the time required for new sales personnel to reach full productivity; the risk that our final results for the third quarter of 2026 differ from the preliminary results in this release; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; changes in payer claims reimbursement practices and MDxHealth estimates regarding collection amounts for tests; the results of recoupment decisions and related appeals; the impacts and effectiveness of exiting from discontinued operations; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the ExoDx and GPS prostate cancer businesses will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Genomic Prostate Score, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What preliminary third-quarter 2026 revenue does MDxHealth expect?
MDxHealth expects approximately $22.7 million in third-quarter 2026 revenue from continuing operations, compared with $22.7 million in the third quarter of 2025. The prior-year figure was re-presented to exclude Resolve mdx, which is reported as a discontinued operation.
What happened to MDxHealth's full-year 2026 revenue guidance?
MDxHealth suspended its $110–115 million full-year 2026 revenue guidance. The company attributed revenue below expectations to unexpected sales-force turnover following the discontinuation of Resolve mdx.
Has MDxHealth's preliminary third-quarter 2026 financial information been independently reviewed?
MDxHealth's independent registered public accounting firm has not audited, reviewed or performed any procedures on the preliminary financial information. The estimates reflect management's initial review and remain subject to completion of quarter-end financial close and review procedures; actual results may differ materially.